Comparative Pharmacology
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus SPECTAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM IODIDE I 123 versus SPECTAMINE.
SODIUM IODIDE I 123 vs SPECTAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium iodide I 123 is a radioactive isotope that emits gamma radiation. Following oral or intravenous administration, it is rapidly absorbed and selectively concentrated in the thyroid gland via the sodium-iodide symporter (NIS). The emitted gamma rays allow for imaging of thyroid tissue and detection of abnormal uptake patterns.
SPECTAMINE (iofetamine I-123) is a radiopharmaceutical that crosses the blood-brain barrier and localizes in the brain proportional to regional cerebral blood flow. It binds to striatal dopamine transporters (DAT) and is used as a marker for dopamine transporter density.
Oral: 400-800 μCi (14.8-29.6 MBq) for thyroid uptake studies; 150-300 μCi (5.6-11.1 MBq) for thyroid scan. Administer orally as a single dose.
SPECTAMINE (technetium Tc-99m exametazime) is administered intravenously. For brain imaging, the recommended adult dose is 10-20 mCi (370-740 MBq). For white blood cell labeling, the dose is 10-20 mCi (370-740 MBq) after labeling autologous leukocytes.
None Documented
None Documented
13.2 hours (physical T1/2); effective T1/2 ~13 hours in euthyroid; prolonged in hypothyroidism.
Terminal elimination half-life: 13-17 hours; clinically, effective half-life for brain SPECT imaging is 6-9 hours due to redistribution.
Primarily renal (90%) as iodide; small amount feces (<5%) and negligible biliary.
Renal: >90% as unchanged drug within 24 hours; biliary/fecal: <5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical